Table 1

Data for non-diabetic participants in 11 trials included in meta-analysis

TrialActive vs control daily therapiesNon-DM patients/total cohort (%)N (without DM) on niacin/controlDescriptionFollow-up (months)Method of DM diagnosisMean BMI (kg/m2)Mean age (years)Frequency of within-trial FPG measurement
Coronary drug project6Niacin 3 g vs placebo3436/3906 (88)988/2448Men with previous MI60I, II, III26.152.5Yearly
FATS7Niacin 4 g/colestipol 30 mg vs placebo or placebo/colestipol 30 mg82/82 (100)36/46Men with high ApoB and family history of CHD32II26.746.76 monthly
ADMIT8Niacin 3 g vs placebo343/468 (73)173/170Peripheral artery disease, with and without DM11II27656 weekly
ARBITER-213ERN 1 g vs placebo (background statin)121/167 (72)63/58CHD and HDL <1.16 mmol/L12II, III29.1*67*At 12 months
Moore et al15ERN 2 g/atorvastatin±colsevelam 3.8 g vs placebo/atorvastatin108/123 (88)70/38CHD or carotid atherosclerosis with high ApoB and LDL-c12I, II, III29.6*55*At months 5 and 12
SEACOAST I9ERN 1 g/simvastatin 20 mg or 2 g/20 mg vs simvastatin 20 mg248/314 (79)150/98High CVD risk with mixed dyslipidaemia4Not stated28.2*56.6*At week 24
Guyton et al10ERN 2 g/ezetimibe 10 mg/simvastatin 20 mg vs ezetimibe 10 mg/ simvastatin 20 mg798/942 (85)569/229Type IIa or Type IIIb hyperlipidaemia16I, II, III30.1*57.2*4 weekly
Maccubbin et al11ERN 2 g/LRPT 40 mg or ERN 2 g vs placebo (with or without background statin)1356/1613 (84)1124/232Primary hypercholesterolaemia or mixed dyslipidaemia4I, II29*At week 24
ARBITER-614ERN 2 g vs ezetimibe 10 mg (background statin)218/363 (60)114 /104CHD or high CHD-risk, with LDL <2.6 mmol/L and low HDL14II, III30.9*64.5*At months 2, 8 and 14
AIM-HIGH1ERN 1.5–2 g/simvastatin 40–80 mg vs placebo/simvastatin 40–80 mg (with or without ezetimibe 10 mg)2256/3414 (66)1130/1126Atherosclerotic CVD and LDL <1.81 mmol/L36Not stated63.7*6 monthly
HPS2-THRIVE2ERN 2 g/LRPT 40 mg/simvastatin 40 mg vs placebo/simvastatin 40 mg (with or without ezetimibe 10 mg)17 374/25 673 (68)8704/8670Patients with CVD47†I, II27.7*64.9*None
Total26 340/37 065 (71)13 121/13 219
  • I=adverse event report or physician report; II=glucose lowering therapy; III=raised fasting plasma glucose (≥7.0 mmol/L) on two occasions.

  • *Data from total cohort (including diabetics at baseline).

  • ‡Weighted mean follow-up.

  • AIM-HIGH, Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes; BMI, body mass index; CHD, coronary heart disease; CVD, cardiovascular disease; DM, diabetes mellitus; ERN, extended release niacin; FPG, fasting plasma glucose; HPS2-THRIVE, Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events; HDL,high-density lipoprotein; LDL, low-density lipoprotein; LRPT, laropiprant; MI, myocardial infarction.